Hematology

Spectrila

Product Description

Spectrila is a chemotherapy drug. Its active substance is asparaginase, an enzyme that breaks down asparagine. In contrast to normal cells, lymphoblastic tumor cells have a very limited capacity for synthsising their own asparagine. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells. Spectrila is the best quality non-pegylated E. coli asparaginase globally.

Active Ingredient

Asparaginase

Mode of Action

The rASNase production is a bacterial cell, the human gut bacterium Escherichia coli (E. coli) that is widely used for biotechnological purposes. L-Asparaginase (ASNase) is an enzyme which breaks down extracellular asparaginase to aspartic acid and ammonia. As a result, availability of asparaginase is reduced which causes cell function impairment in cells depending on an external supply. For instance, cancer cells in acute lymphoblastic leukaemia (ALL), a malignant disease of the haematopoietic system which is characterised by an uncontrolled proliferation of immature blood cells, require an external source of asparaginase. Hence, ASNase is a central component of treatment regimes for children and adults with ALL. By breaking down asparaginase, ASNase inhibits the growth of the lymphatic leukaemic cells and thereby contributed decisively to the overall result of the cancer treatment. Optimization of th eproduction and purification procedures according to the most recent guidelines for biotechnology-derived proteins lead to a new asparaginase preperation, Spectrila. Possibility of large-scale production can help to ensure the long-term availability of this essential drug for the treatment of ALL. (marketing material)

Administration

Intravenous infusion

Indication

Acute lymphoblastic leukaemia (ALL) as a component of antineoplastic combination therapy in paediatric patients from birth to 18 years and adults

Dosage

Powder for concentrate for solution for infusion:

10,000 units

Not all pack sizes may be marketed.

Materials

Abbreviated product information

Open link External Link

Discover more

Rheumatology

Key rheumatological treatment improved

Rheumatic diseases imply a range of chronic treatment needs across a broad spectrum of patients. With the optimisation of a key treatment in this area, medac has succeeded in bringing a significant improvement to patients' quality of life.

Urology

Addressing unmet needs with urological therapies

Urology is a focus area of highest importance for medac. We have been active in this field from almost the very beginning of our company and are focused on supplying a range of proprietary products that address a variety of unmet therapeutic needs.

Hematology

Innovative and life-saving treatment options

Hematology is a focus area of high importance for medac. To find new treatment approaches for rare diseases, medac addresses critical needs in hematology and has developed innovative products for therapies before and after stem cell transplantation.